Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer

Area of Science:

• Immunology
• Oncology
• Vascular Biology

Background:

• Endoglin (CD105) is over-expressed on breast tumor neovasculature, making it a target for anti-angiogenic therapy.
• Targeting tumor angiogenesis is a key strategy in cancer treatment.

Purpose of the Study:

• To evaluate the anti-angiogenic and anti-tumor effects of an oral DNA vaccine encoding murine endoglin.
• To investigate the immune mechanisms underlying the vaccine's efficacy.

Main Methods:

• An oral DNA vaccine encoding murine endoglin was delivered via attenuated Salmonella typhimurium to Peyer's patches.
• Immune responses, including CD8+ T cell activation and dendritic cell activity, were assessed.
• Angiogenesis and tumor metastasis were evaluated in a prophylactic setting using D2F2 breast carcinoma cells in mice.

Main Results:

• The endoglin vaccine activated antigen-presenting dendritic cells and elicited CD8+ T cell responses against endoglin-positive cells.
• Significant suppression of angiogenesis was observed in mice receiving the endoglin vaccine compared to controls.
• The vaccine effectively suppressed pulmonary metastasis of breast carcinoma cells.

Conclusions:

• A CD8+ T cell-mediated immune response induced by the endoglin DNA vaccine can suppress tumor angiogenesis and metastasis.
• This vaccine strategy shows promise for future breast cancer therapies by targeting tumor vasculature.